跳至主要内容
临床试验/JPRN-UMIN000007069
JPRN-UMIN000007069已完成未知

Effectiveness of aripiprazole augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder with poor insight - Effectiveness of aripiprazole augmentation in SSRI-refractory OCD with poor insight

Hyogo College of Medicine0 个研究点目标入组 116 人开始时间: 2012年1月16日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
116

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who meet DSM-IV-TR for schizophrenia, schizoaffective disorder, and bipolar disorder. Patients who have a HAM-D of 21 and greater. Patients who have significant mental retardation and pervasive development disorder. Patients who are comatose and strongly affected by centrally-acting suppressants such as barbiturates or anesthetics. Patients who have received adrenaline. Patients known to have a history or complication of allergy to aripiprazole. Patients with a history or a complication of diabetes. Women who are pregnant, possibly pregnant, or breast-feeding. Patients who have been judged by the investigator to be inappropriate for inclusion in the trial for any other reasons. Patients who have a complication of serious physical disorder.

研究者

相似试验